Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Rat (Rattus) TNFRSF11A Antikörper:
anti-Mouse (Murine) TNFRSF11A Antikörper:
anti-Human TNFRSF11A Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal TNFRSF11A Primary Antibody für CyTOF, FACS - ABIN252472
Fiumara, Snell, Li, Mukhopadhyay, Younes, Gillenwater, Cabanillas, Aggarwal, Younes: Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. in Blood 2001
Show all 15 Pubmed References
Human Monoclonal TNFRSF11A Primary Antibody für FACS, IHC (p) - ABIN252036
Lee, Kim, Jun, Yoo, Woo, Choi, Lee, Song, Sohn, Park-Min, Ivashkiv, Ji: Direct inhibition of human RANK+ osteoclast precursors identifies a homeostatic function of IL-1beta. in Journal of immunology (Baltimore, Md. : 1950) 2010
Show all 10 Pubmed References
Human Monoclonal TNFRSF11A Primary Antibody für CyTOF, ELISA (Capture) - ABIN4900544
Vernal, Dutzan, Hernández, Chandía, Puente, León, García, Del Valle, Silva, Gamonal: High expression levels of receptor activator of nuclear factor-kappa B ligand associated with human chronic periodontitis are mainly secreted by CD4+ T lymphocytes. in Journal of periodontology 2006
Show all 6 Pubmed References
Human Monoclonal TNFRSF11A Primary Antibody für FACS - ABIN4897927
Riegel, Maurer, Prior, Stegmaier, Heppert, Wagner, Hänsch: Human polymorphonuclear neutrophils express RANK and are activated by its ligand, RANKL. in European journal of immunology 2012
Mouse (Murine) Monoclonal TNFRSF11A Primary Antibody für FACS, IP - ABIN2479562
García-Pérez, Noguera, Hermenegildo, Martínez-Romero, Tarín, Cano: Alterations in the phenotype and function of immune cells in ovariectomy-induced osteopenic mice. in Human reproduction (Oxford, England) 2006
TNFalpha and RANKL promote osteoclastogenesis by upregulating RANK via the NFkappaB pathway.
Results from this study demonstrate that RANK signalling in NPY (zeige NPY Antikörper) neurons is involved in modulating NPY (zeige NPY Antikörper) levels and through that matching bone mass to body weight.
the investigation of RANK and RANKL (zeige TNFSF11 Antikörper) as possible novel immunotherapy targets in cancer is a rational approach. Here we have defined the mechanism of action of RANKL (zeige TNFSF11 Antikörper)-RANK blockade in combination with anti-CTLA4 (zeige CTLA4 Antikörper), and provide insight into the combination efficacy observed in the case reports.
Insulin induces RANK expression via ERK1/2, which contributes to the enhancement of osteoclast differentiation.
This indicated that RANK might be the binding target of baicalin. In sum, our findings revealed baicalin increased osteoclast maturation and function via p-ERK (zeige EPHB2 Antikörper)/Mitf (zeige MITF Antikörper) signalling. In addition, the results suggest that baicalin can potentially be used as a natural product for the treatment of bone fracture
RANKL (zeige TNFSF11 Antikörper)/RANK control progenitor cell expansion and tumorigenesis in inherited breast cancer.
Artesunate inhibits RANKL (zeige TNFSF11 Antikörper)-induced osteoclastogenesis by suppressing the NF-kappaB (zeige NFKB1 Antikörper) signaling pathway.
Data suggest that mutations at position I248 in DE-loop of murine RANKL (zeige TNFSF11 Antikörper) have effects on interaction of RANKL (zeige TNFSF11 Antikörper) with RANK and on subsequent activation of osteoclastogenesis by this hetero-multimer. (RANKL (zeige TNFSF11 Antikörper) = osteoclast differentiation factor (zeige TNFSF11 Antikörper); RANK = tumor necrosis factor (zeige TNF Antikörper) receptor superfamily, member 11a protein)
The persistence of bone erosion and synovial osteoclasts in Rank-deficient mice, and the ability of TNF (zeige TNF Antikörper)/IL-6 (zeige IL6 Antikörper) to induce osteoclastogenesis, suggest that more than one cytokine pathway exists to generate these bone-resorbing cells in inflamed joints.
Muscle RANK deletion had no significant effects on the sham or denervated slow-twitch soleus muscles. These data identify a novel role for RANK as a key regulator of Ca(2 (zeige CA2 Antikörper)+)storage and SERCA (zeige ATP2A3 Antikörper) activity, ultimately affecting denervated skeletal muscle function.
study identified the second disease gene for DOS. TNFRSF11A isoforms may have the different roles in skeletal development and metabolism
The mRNA expression of RANK was highest in prostate tumour tissue from patients with bone metastases as compared to BPH or locally confined tumours, also shown in clinical subgroups distinguished by Gleason Score or PSA level.
For the RANK gene, the AGTGC haplotype was associated with the lowest risk of presenting chronic joint pain in individuals without TMD (zeige TTN Antikörper) (P=0.03). This study supports the hypothesis that changes in the OPG (zeige TNFRSF11B Antikörper) and RANK genes influence the presence of chronic joint pain in individuals with and without TMD (zeige TTN Antikörper).
In this study, whole exome sequencing (WES) was successfully used in six patients with malignant infantile osteopetrosis (zeige CSF1 Antikörper) (MIOP) and identified mutations in four MIOP-related genes (CLCN7 (zeige CLCN7 Antikörper), TCIRG1 (zeige TCIRG1 Antikörper), SNX10 (zeige SNX10 Antikörper), and TNFRSF11A).
triple-negative breast cancer (TNBC) patients that expressed both RANK and RANKL (zeige TNFSF11 Antikörper) proteins had significantly worse RFS and OS than patients with RANK-positive, RANKL (zeige TNFSF11 Antikörper)-negative tumors. RANKL (zeige TNFSF11 Antikörper) was an independent, poor prognostic factor for RFS and OS in multivariate analysis in samples that expressed both RANK and RANKL (zeige TNFSF11 Antikörper).
RANK is increased in hormone receptor (zeige NR4A1 Antikörper) negative and basal breast cancer, and correlates with worse recurrence-free survival and risk of bone metastasis.
Studies showed that the central hypothalamic-pituitary regulatory system, via it's relative hormones, seems to control OPG/RANKL (zeige TNFSF11 Antikörper)/RANK system function, and the pulsatility and circadian rhythmicity of these hormones may induce an oscillatory fluctuation of the OPG/ RANKL (zeige TNFSF11 Antikörper) ratio. Also, psycological characteristics may provoke a shift of the OPG/ RANKL (zeige TNFSF11 Antikörper) ratio towards an unbalanced or a balanced status. [review]
Studies strongly implicates RANK and RANKL as key molecules involved in the initiation of BRCA1-associated breast cancer. [review]
RANK is frequently expressed by cancer cells in contrast with RANKL (zeige TNFSF11 Antikörper) which is frequently detected in the tumor microenvironment, and together they participate in every step in cancer development. (Review)
EGFR (zeige EGFR Antikörper) and RANK combinatorial in vitro analyses revealed a significant upregulation of AKT (zeige AKT1 Antikörper) and ERK (zeige EPHB2 Antikörper) signaling after EGF (zeige EGF Antikörper) stimulation in cell lines and also an increase of breast cancer cell invasiveness.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptors can interact with various TRAF family proteins, through which this receptor induces the activation of NF-kappa B and MAPK8/JNK. This receptor and its ligand are important regulators of the interaction between T cells and dendritic cells. This receptor is also an essential mediator for osteoclast and lymph node development. Mutations at this locus have been associated with familial expansile osteolysis, autosomal recessive osteopetrosis, and Paget disease of bone. Alternatively spliced transcript variants have been described for this locus.
tumor necrosis factor receptor superfamily member 11A
, tumor necrosis factor receptor superfamily, member 11a, NFKB activator
, receptor activator of nuclear factor-kappa B
, tumor necrosis factor receptor superfamily member 11A-like
, osteoclast differentiation factor receptor
, receptor activator of NF-KB
, receptor activator of NF-kappaB
, loss of heterozygosity, 18, chromosomal region 1